The Cognitive‐Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch‐Cog study cohort by Jutten, Roos J. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The CognitiveFunctional Composite is sensitive to clinical
progression in early dementia: Longitudinal findings from the
CatchCog study cohort
Citation for published version:
Jutten, RJ, Harrison, JE, Brunner, AJ, Vreeswijk, R, Deelen, RAJ, De Jong, FJ, Opmeer, EM, Ritchie, CW,
Aleman, A, Scheltens, P & Sikkes, SAM 2020, 'The CognitiveFunctional Composite is sensitive to clinical
progression in early dementia: Longitudinal findings from the CatchCog study cohort', Alzheimer's and
Dementia: Translational Research and Clinical Interventions, vol. 6, no. 1. https://doi.org/10.1002/trc2.v6.1
Digital Object Identifier (DOI):
10.1002/trc2.v6.1
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Alzheimer's and Dementia: Translational Research and Clinical Interventions
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Received: 13 February 2020 Accepted: 6March 2020 Published online: 17 April 2020
DOI: 10.1002/trc2.12020
R E S E A RCH ART I C L E
The Cognitive-Functional Composite is sensitive to clinical
progression in early dementia: Longitudinal findings from the
Catch-Cog study cohort
Roos J. Jutten1 John E. Harrison1,2,3 A.J. Brunner1 R. Vreeswijk4 R.A.J. van
Deelen4 Frank Jan de Jong5 EstherM. Opmeer6,7 CraigW. Ritchie8
André Aleman6 Philip Scheltens1 Sietske A.M. Sikkes1,9
1Alzheimer Center Amsterdam, Department of
Neurology, AmsterdamNeuroscience,
Amsterdam, AmsterdamUMC, the Netherlands
2Metis Cognition Ltd,Wiltshire, UK
3Institute of Psychiatry, Psychology &
Neuroscience, King’s College London, London,
UK
4Department of Geriatrics, Spaarne Gasthuis,
Haarlem, the Netherlands
5Department of Neurology, ErasmusMedical
Center, Rotterdam, the Netherlands
6Department of Neurosciences, University of
Groningen, UniversityMedical Center
Groningen, Groningen, the Netherlands
7Department of Health and SocialWork,
University of Applied SciencesWindesheim,
Zwolle, the Netherlands
8Centre for Dementia Prevention, University of
Edinburgh, Edinburgh, UK
9Department of Clinical, Neuro- &
Developmental Psychology, Vrije Universiteit
Amsterdam, Amsterdam, the Netherlands
Correspondence
Roos J. Jutten,AlzheimerCenterAmster-
dam&DepartmentofNeurology,Amsterdam
UMC, locationVUmc,P.O.Box7057, 1007MB
Amsterdam,TheNetherlands.
E-mail: r.jutten@amsterdamumc.nl
Abstract
Introduction: In an attempt to capture clinically meaningful cognitive decline in early
dementia, we developed the Cognitive-Functional Composite (CFC). We investigated
the CFC’s sensitivity to decline in comparison to traditional clinical endpoints.
Methods: This longitudinal construct validation study included 148 participants with
subjective cognitive decline, mild cognitive impairment, or mild dementia. The CFC
and traditional tests were administered at baseline, 3, 6, and 12 months. Sensitivity to
changewas investigated using linear mixedmodels and r2 effect sizes.
Results: CFC scores declined over time (𝛽 = −.16, P < .001), with steepest decline
observed in mild Alzheimer’s dementia (𝛽 = −.25, P < .001). The CFC showed medium-
to-large effect sizes at succeeding follow-up points (r2= .08-.42), exhibiting greater
change than the Clinical Dementia Rating scale (r2= .02-.12). Moreover, change on the
CFC was significantly associated with informant reports of cognitive decline (𝛽 = .38,
P< .001).
Discussion:By showing sensitivity to decline, the CFC could enhance themonitoring of
disease progression in dementia research and clinical practice.
K EYWORD S
Alzheimer’s disease, cognition, dementia, instrumental activities of daily living, mild cognitive
impairment, outcomemeasures
1 INTRODUCTION
As Alzheimer’s disease (AD) clinical trials are increasingly target-
ing earlier disease stages,1 it is of crucial importance that outcome
measures of efficacy are adapted to these novel target populations.2
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
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Common guidance for the selection of acceptable endpoints for use
in clinical trials, as well as observational studies in general, holds that
selected measures must exhibit acceptable levels of reliability, validity,
and sensitivity to change in the target population.3 Furthermore, these
tests must be free of range restrictions, and ideally be brief so as to
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avoid fatigue or ennui effects, as well as appropriate for cross-cultural
use.4
While commonly employed cognitive and functional measures
selected for AD clinical trials have tended to demonstrate acceptable
levels of reliability, they have fared less well with regard to their valid-
ity and sensitivity to change over time. For example, floor- and ceiling
effects in scoring have been observed on parts of the Alzheimer’s Dis-
ease Assessment Scale–Cognitive subscale (ADAS-Cog)5 when admin-
istered in mild cognitive impairment (MCI) and mild dementia, limiting
its sensitivity to change over time.6–8 Moreover, it has been questioned
to what extent change on the ADAS-Cog, as well as other cognitive
tests, reflects clinically meaningful changes.9,10 Challenges regarding
validity have also been encountered when measuring functional skills
in individuals withMCI ormild dementia, as most existingmeasures do
not feature complex instrument activities of daily living (IADL), which
aremost prone to early cognitive decline, or items indexing contempo-
rary everyday activities such as electronic banking and self-organized
travel arrangements.11–13
In the past few years the AD research community has sought to
identify novel methods that yield a single, unitary, and valid mea-
sure of efficacy, including elements of both cognitive and functional
performance.14 This has also been encouraged by the Food and Drug
Administration and European Medicine Agency in their guidelines for
AD drug trials.15,16 A measure that has found favor as a combined
measure is the Clinical Dementia Rating (CDR) scale,17 particularly
its sum of boxes (CDR-SB) scoring.18,19 However, a challenge when
employing the CDR has been the modest rate of change over time
when the scale is employed in those living with the very earliest man-
ifestations of the disease.20 Further challenges have been that the
CDR-SB scoring requires extensive training, is subject to variability
among ethnicities and languages, and showed only modest inter-rater
reliability.21
To fulfil the need for a reliable, valid, sensitive, and clinically mean-
ingful measure of cognitive decline in early clinical stages of AD, the
Cognitive-Functional Composite (CFC) has been designed.22 The CFC
yields a brief measure (20-25 minutes) of both cognition and func-
tion, comprising seven existing cognitive tests focusing onmemory and
executive functioning23 and the Amsterdam IADL Questionnaire (A-
IADL-Q).24–26 We have previously demonstrated good psychometric
qualities of the CFC, such as good test-retest reliability, feasibility of
use, validity, and quality for the target population.27,28 The current
study aimed to investigate the sensitivity to change of the CFC in indi-
viduals withMCI andmild AD dementia over a period of 1 year, as well
as performance of the same individuals over the same period on the
CDR-SB,18 ADAS-Cog,5 and Alzheimer’s Disease Cooperative Study–
Activities of Daily Living (ADCS-ADL) scale.29 Second, we explored
whether the CFC could be of use to capture change in individuals with
subjective cognitive decline (SCD), and Dementia with Lewy Bodies
(DLB) which is the second most common cause of dementia. We also
sought to determine the clinical meaningfulness of decline detected by
the CFC, by associating change on the CFC with informant reports of
decline in everyday abilities.
HIGHLIGHTS
• The Cognitive-Functional Composite (CFC) is sensitive to
clinical progression inmild Alzheimer’s dementia
• The CFC exhibits greater sensitivity to change than tradi-
tional clinical endpoints
• Change on the CFC is related to informant-reports of cog-
nitive decline
RESEARCH INCONTEXT
• Systematic review: The authors reviewed PubMed for lit-
erature on existing measures to assess disease progres-
sion in Alzheimer’s disease (AD). There is still an urgent
need for reliable, valid, and sensitive outcome measures
that could improve the monitoring of progression in early
clinical stages of AD.
• Interpretation: Our findings imply that the Cognitive-
Functional Composite (CFC) is sensitive to clinical mean-
ingful cognitive decline in early AD, and provides a supe-
rior alternative approach to the use of traditional clinical
endpoints. The CFC could thereby improve the monitor-
ing of disease progression, and enhance the evaluation of
disease-modifying therapies targeting early clinical stages
of AD.
• Future directions: This manuscript has important implica-
tions for AD research and clinical practice, as it provides
guidance for the selection of outcome measures to evalu-
ate disease progression in early AD. It also highlights the
importance of the inclusion of a sensitive functional mea-
sure to capture clinically meaningful changes.
2 METHODS
2.1 Study design and participants
In this longitudinal analysis, we employed data from the Capturing
Change in Cognition (Catch-Cog) study: an international, observa-
tional cohort-study with baseline, 3-, 6-, and 12-month assessments.22
Participants (N = 173) and their study partners were included at the
(1) Alzheimer Center Amsterdam, Amsterdam UMC, the Netherlands
(AC, n = 102); (2) Alzheimer Center of the Erasmus Medical Center,
Rotterdam, the Netherlands (EMC, n = 14); (3) University Medical
Center Groningen, the Netherlands (UMCG, n = 39); or (4) the Centre
for Dementia Prevention, Edinburgh, Scotland (EDI, n = 18). Before
inclusion, participants had undergone a standard diagnosticwork-up in
their memory clinic, including at leastmedical history, and neurological
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and neuropsychological examination. A subset of participants included
in the AC had AD biomarkers available as measured by a cerebrospinal
fluid lumbar puncture. Amyloid positivity was based on amyloid beta
(A𝛽) 1-42 values (cut-off ≤813 pg./mL).30 In all centers, clinical diag-
noses were made in a multidisciplinary consensus meeting including at
least a neurologist, psychiatrist, and neuropsychologist. Additionally
in the UMCG, participants were recruited via advertisements in local
newspapers. Individuals willing to participate were screened by a
neuropsychologist and neurologist to investigate whether they were
eligible for the current study.
Participants were included in the Catch-Cog study when they met
the research criteria for SCD,31 or the clinical criteria for MCI,32
possible or probable AD dementia,33 or possible or probable DLB
dementia.22 Other inclusion criteriawere: (1)Mini-Mental State Exam-
ination (MMSE) score≥ 18,34 (2) age≥50, and (3) availability of a study
partner who was able to understand the study information and willing
to participate. Exclusion criteria were (1) presence of another neuro-
logical disorder than AD or DLB, (2) presence of a major psychiatric
disorder such as severe personality disorder or depression (Geriatric
Depression Scale score≥6),35 (3) current abuse of alcohol or drugs, (4)
simultaneously participating in a clinical trial.
Data were collected between October 2016 and December 2018.
The Medical-Ethical Committee of the VU University Medical Cen-
ter approved the study for all Dutch centers. The South East Scot-
land Research Ethic Committee approved the study for the Scottish
site. All participants and their study partners providedwritten and oral
informed consent.
2.2 The cognitive-functional composite
Full details on the selected CFC measures have been reported
elsewhere.22,28 Briefly, the cognitive test battery of the CFC includes
the three ADAS-Cog memory subscales Word Recognition (score
range 0-12), Word Recall (score range 0-10), and Orientation (score
range 0-8);5 the Controlled Oral Word Association Test (COWAT;
letters D-A-T in Dutch and F-A-S in English, 60 seconds);36; Cate-
gory Fluency Test (CFT; animals, 60 seconds);36 Digit Span Backward
(DSB, score range 0-14);37 and Digit Symbol Substitution Test (DSST,
90 seconds).38 The functional component comprises the short version
of the A-IADL-Q, a computerized, informant-based questionnaire con-
sisting of 30 items covering a broad range of complex IADL.26 Example
items include cooking, managing finances, and modern activities such
as applying everyday technology.24,25 For each item, difficulty in per-
formance is rated on a five-point Likert scale (ranging from “no diffi-
culty in performing this task” to “no longer able to perform this task”).
Scoring is performed using item response theory (IRT), resulting in a
latent trait score (z-score) reflecting one’s IADL functioning.25
To createCFC scores, the directionality of the threeADAS-Cog sub-
test scores is reversed so that higher scores reflected better perfor-
mance. Subsequently, all cognitive subtest scores are z-transformed
using baseline total group means and standard deviations (SD). The
cognitive composite is computed as a weighted z-score of all seven
cognitive subtests if at least five tests are available, with all avail-
able tests being equally weighted. This approach was chosen as it was
previously shown to provide a reliable scoring method for this cog-
nitive composite.23 The functional component score is the A-IADL-
Q latent trait z-score.25 The overall CFC score is computed as an
equally weighted z-score of the cognitive composite and A-IADL-Q
scores, with higher scores indicating better performance. We previ-
ously showed that this scoringmethod results in a valid CFC score that
is in line with clinical manifestations of different diagnostic groups and
not affected by range restrictions in scoring.28
2.3 Referencemeasures
As previously reported,22 commonly employed AD clinical trial mea-
sures were administered, including the ADAS-Cog-13 (total score
range 0-85),5 ADCS-ADL (total score range 0-78),29 and the CDR-SB
(total score range 0-18).18 The study partner version of the Cognitive
Function Instrument (CFI) was administered as anchormeasure of clin-
ical decline. The CFI includes 14 items that enquire about decline in
day-to-day cognitive and functional abilities, comparedwith 1 year ago
(score range 0-14, higher scores reflectingmore decline).39 It was orig-
inally developed to track decline in preclinical stages of AD, but the
study partner versionwas also found to be useful to assess decline indi-
viduals with subtle cognitive impairment.40
2.4 Procedures
Study visits took place at the hospital or the participant’s home,
depending on the participant’s preference. At baseline, a number of
74 participants (43%) chose testing at home, and we aimed to keep
assessment location constant within participants over time. CFC and
traditional tests were administered at each follow-up time-point, so
that head-to-head comparisons could be made between all measures.
A trained rater administered the cognitive tests according to standard-
ized instructions, starting with the MMSE and followed by the cog-
nitive part of the CFC and the remaining ADAS-Cog-13 tests. In the
meantime, the study partner completed the A-IADL-Q and CFI inde-
pendently on an iPad. Finally, the rater completed the ADCS-ADL and
CDR interview with the study partner. The content of each study visit
was similar, except that existing, validated parallel versions were used
forWord Recognition andWord Recall, specifically List 1, 2, 4, and 5.5
A shortened protocol was used in the SCD and DLB participants, as
it was not our purpose to compare the CFC to traditional tests that
were not designed for these groups. Therefore, SCD and DLB partici-
pantswho only underwent theMMSE and cognitive battery of theCFC
while their study partner completed the functional component of the
CFC.
4 of 11 JUTTEN ET AL.
Baseline
n=173
3 months
n=107
6 months
n=142
12 months
n=131
n=2 SCD
n=13 MCI
n=7 AD
n=3 DLB
n=11 withdrew from study 
n=25 withdrew from study 
n=6 withdrew from study 
n=41 skipped 3 months 
visit for logistic reasons 
n=1 SCD
n=3 MCI
n=2 AD
n=5 MCI
n=6 AD
F IGURE 1 Flow diagram providing an overview of the sample size at each time point
2.5 Statistical analyses
Statistical analyses were performed using R version 3.5.3 (R Core
Team, 2016). Statistical significance was set at P < .05. Baseline dif-
ferences between groups were investigated using 𝜒2 or Fisher’s exact
tests when appropriate, one-way analyses of variance followed by
Hochberg’s post-hoc tests, and independent t-tests for measures only
available for theMCI and AD groups.
Sensitivity to change over time of the CFC was investigated using
linear mixed models (LMM) with random effects for subject (intercept
and slope) and center (intercept). All subjects with at least one follow-
up assessment available were included in these models. We ran sepa-
ratemodels with CFC, CC, andA-IADL-Q scores as dependent variable
and time as independent variable (measured on a continuous level).
Second, we repeated these models while adjusting for age, sex, edu-
cation, diagnosis, and the interaction between time and diagnosis. If a
significant effect of the time*diagnosis term was found, analyses were
repeated stratified per diagnosis. In our sample of MCI and mild AD
subjects, separate LMM models adjusting for age, sex, and education
were also performed with the ADAS-Cog, ADCS-ADL, and CDR-SB as
dependent variables and time as independent variable. To control for
the different scaling properties and to allow for proper head-to-head
comparisons, the ADAS-Cog and CDR-SB total scores were reversed
so that higher scores reflected better performance, and subsequently
z-transformed using total group baseline means and SDs of the com-
bined sample of MCI and AD subjects. ADCS-ADL scores were stan-
dardized using the same approach.
To compare the sensitivity of the CFC and traditional tests at differ-
ent time points, r2 effect sizes of change were calculated from baseline
to each follow-up point (3, 6, and 12 months). Effect sizes were eval-
uated based on predefined cut-offs, with .01 defined as small, .09 as
medium, and .25 as large effects.
To assess the clinical meaningfulness of observed change on the
CFC and traditional tests, separate linear regression analyses were
performed for each test in our combined sample of MCI and AD par-
ticipants. The CFI score obtained at 12 months follow-up was used as
dependent variable, and annual CFC change scores were inserted as
independent variable while adjusting for age, sex, and education.
Sensitivity analyses. To explore whether change on the CFCwas spe-
cific to AD-related decline as opposed to change over time in general,
we repeated the LMM analyses for the CFC in a subset of amyloid
positive participants. Second, differences among study cohorts were
explored by repeating the LMM analyses for the CFC and traditional
test scores separately for each study center.
3 RESULTS
3.1 Study sample characteristics
A total of 173 subjects were included (age = 71.3 ± 8.5, 42% female,
n = 14 SCD; n = 75 MCI; n = 72 AD; n = 12 DLB) in the Catch-Cog
study, ofwhichn=131 (76%) subjects completed the12-monthassess-
ment (Figure 1). Subjects that withdrew during the study (n= 42; age=
72.7±8.4; 39%female; n=3SCD,n=21MCI, n=15AD,n=3DLB)did
not differ regarding age, sex, education, and clinical severity at baseline
from those who completed the study.
A number of n = 148 participants (86%) had at least one follow-
up available and were included in the current study. Table 1 presents
the baseline characteristics for this sample as well as separately for
each clinical group, revealing that groups did not differ regarding age,
sex, and education. Mean baseline CFC scores differed among groups
(SCD = .91 ± .61; MCI = .28 ± .50; AD = −.34 ± .65; DLB = −.51 ± .75,
F= 25.84, P< .001), with post-hoc comparisons showing a significantly
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TABLE 1 Demographic and clinical characteristics at baseline, for the total included sample (N= 148) and separately for each clinical group
Total (N= 148)
SCD (n= 12) MCI (n= 62) AD (n= 65) DLB (n= 9) P –Value Post-hoc comparisonsa
Demographics Age 71.3 (8.4) 68.3 (7.0) 73.6 (8.1) 71.2 (9.0) 69.3 (6.4) .106 n.a.
Female (%) 66 (45%) 8 (66.7%) 23 (37.1%) 33 (50.8%) 2 (22.2%) .087 n.a.
Education 13.8 (3.9) 15.2 (5.1) 14.0 (3.8) 13.3 (3.9) 14.4 (3.1) .40 n.a.
MMSE 25.7 (3.2) 29.2 (1.3) 26.9 (2.3) 24.2 (3.4) 24.0 (3.0) <.001 SCD>AD; SCD>DLB;
MCI>AD;MCI>DLB
CFCmeasures CC .00 (.66) .84 (.53) .20 (.51) −.27 (.61) −.49 (.70) <.001 SCD>MCI>AD;
SCD>DLB;MCI>DLB
A-IADL-Q .00 (.92) .99 (.80) .37 (.66) −.42 (.89) −.66 (.60) <.001 SCD>AD;MCI>AD;
SCD>DLB;MCI>DLB
CFC score .00 (.72) .91 (.61) .28 (.50) −.34 (.65) −.51 (.75) <.001 SCD>MCI>AD;
SCD>DLB;MCI>DLB
Traditional tests ADAS-Cog 24.9 (7.6) n.a. 22.0 (6.8) 28.2 (7.0) n.a. .106 n.a.
ADCS-ADL 66.4 (8.5) n.a. 67.8 (7.0) 64.3 (9.4) n.a. <.001 n.a.
CDR-SB 3.8 (2.3) n.a. 2.8 (1.9) 4.9 (2.0) n.a. <.001 n.a.
ADAS-Cog, Alzheimer’sDiseaseAssessment Scale–Cognitive subscale; ADCS-ADL, Alzheimer’sDiseaseCooperation Study–Activity ofDaily Living; A-IADL-
Q, Amsterdam IADL Questionnaire; CC, Cognitive Composite; CDR-SB, Clinical Dementia Rating Sum of Boxes; CFC, Cognitive-Functional Composite;
MMSE,Mini-Mental State Examination; n.a., not applicable.
aBased onHochberg’s post-hoc tests.
higher score for SCD compared to MCI, as well as for MCI compared
to AD and DLB dementia (Table 1). A similar pattern was observed on
the traditional tests, except that no significant differences were found
in the ADAS-Cog scores between theMCI and AD group (Table 1).
3.2 Sensitivity to change over time of the CFC in the
total sample
Overall, CFC scores declined over time (𝛽 =−.15, 95%CI [−.10 to−20],
P < .001), and we found that this association was independent of age,
sex, education, and diagnosis at baseline (corrected 𝛽 =−.16, 95% con-
fidence interval [CI; −.10 to −22], P < .001). However, a significant
time*diagnosis interaction was found (𝛽 = −.18, P < .001), and there-
fore analyses were repeated stratified per clinical group. The results
arepresented inFigure2, showing thatdeclineon theCFCwasonly sig-
nificant in themild AD group (𝛽 =−.25, 95%CI [−.33 to−18], P< .001).
A steeper decline was observed in DLB; however, this effect did not
reach statistical significance (𝛽 =−.47, P= .096).
3.3 Comparison between the CFC and traditional
measures inMCI andmild AD
Figure 3 displays change on the CFC components and the traditional
tests adjusted for age, sex, and education, separately for the MCI and
AD groups. Tables S1 and S2 in supporting information show the cor-
responding regression coefficients.We found a significant decline in A-
IADL-Qscore inMCI (𝛽 =−.15,P= .03),whereas noneof the traditional
measures declined inMCI (Table S2).
All CFC scores and traditional tests scores declined over 1 year
in AD (Figure 3, Tables S1 and S2). Effect sizes of change at all
follow-up time-points on the CFC and traditional tests are pre-
sented in Figure 4. The CFC showed a small-to-medium effect after
3 months (r2 = .08), a medium effect after 6 months (r2 = .12), and
a large effect (r2 = .42) after 12 months, thereby exhibiting greater
change than the CDR-SB all follow-up time points (r2 ranging from
.02–.12).
3.4 Associationwith an anchormeasure of clinical
progression inMCI andmild AD
Figure 5 shows the associations between the CFI score obtained at
12-month follow-up and annual decline on the CFC, CDR-SB, ADCS-
ADL, and ADAS-Cog in our combined sample of MCI and mild AD sub-
jects (n = 127). Linear regression analyses showed that decline on the
CFC was significantly associated with decline in cognitive functioning
as reported on the CFI (𝛽 = .38, 95% CI [.20-.56], P < .001). Among
the traditional tests, only decline on the ADCS-ADL was significantly
related to the CFI score at 12-month follow-up (𝛽 = .26, 95% CI [.07-
.45], P= .009).
3.5 Sensitivity analyses
Sensitivity analyses in amyloid positive participants (n= 37; n= 1 SCD,
n= 7MCI, and n= 29 dementia) showed that CFC scores declined over
time (𝛽 = −.21, 95% CI [−.11 to −.33], P < .001), with decline observed
on both the cognitive and functional component (CC score: 𝛽 = −.16,
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F IGURE 2 Annual change on the Cognitive-Functional Composite, separately for each clinical group
95%CI [−.29 to−.04],P< .001;A-IADL-Qscore: 𝛽 =−.30, 95%CI [−.47
to−.14], P< .001).
Table S3 in supporting information shows the regression coeffi-
cients obtained from LMM stratified per study center. These results
show that CFC scores declined over time in the AC, EMC, and EDI
cohorts, whereas a slight improvement on the CFC (𝛽 = .11, P = .049)
was observed in the UMCG cohort that seemed driven by the cogni-
tive component (𝛽 = .19, P < .001). This was in agreement with results
on the traditional tests, as an improvement on the ADAS-Cog was also
observed in UMCG cohort (𝛽 = .39, P= .003).
4 DISCUSSION
In this longitudinal construct validation study, we demonstrated that
the CFC is sensitive to clinical progression. InMCI, the functional com-
ponent of the CFC detected decline over 1 year, whereas the CDR-SB,
ADAS-Cog, and ADCS-ADL failed to do so. In mild AD dementia, the
CFC captured decline over 1 year, and effect sizes of change suggested
greater sensitivity than the traditionalmeasureswithin 1 year (ie, after
3 and 6 months). Furthermore, annual change on the CFC was associ-
ated with informant reports of cognitive decline.
Worldwide, researchers have addressed the need for outcomemea-
sures that are capable of detecting clinicallymeaningful change in early
AD.14,41 Regulatory agencies have further elevated this importance, as
their guidelines state that evidence of clinically meaningful change is
required for approval of novel therapeutic interventions.15,16 Previous
studies on the CFC already demonstrated its good test-retest reliabil-
ity, feasibility of use, construct validity, and suitability for the target
population (ie, MCI and mild dementia due to AD).26–28 Additionally,
separate studies on the cognitive and functional component previously
showed their sensitivity to change over time.23,42 By performing an
independent longitudinal validation of the CFC, the current study
provides further evidence the CFC meets the requirements for a
clinically meaningful outcomemeasure in early clinical stages of AD.
The current study results bear crucial implications for AD clinical
trials, because the CDR-SB is currently still widely applied as primary
clinical endpoint of efficacy. Previous studies have already indicated
limitations of the CDR-SB as outcome measure of change, relating to
its poor inter-rater reliability,21 and ceiling effects in scoring in MCI
and mild dementia.28 Our current study findings suggest that the CFC
could offer advantages over the use of the CDR-SB asmeasure to eval-
uate clinical progression, by providing a concise and more objective
measure of clinically meaningful cognitive decline.
With regard to other recently developed composites for disease
progression in AD, it is important to consider that CDR perfor-
mance is also a key component of the recently employed Alzheimer’s
Disease Composite Score (ADCOMS).43 However, this measure has
JUTTEN ET AL. 7 of 11
F IGURE 3 Annual decline (corrected for age, sex, and education) on the Cognitive-Functional Composite measures versus traditional tests,
separately in mild cognitive impairment and Alzheimer’s disease
F IGURE 4 Effect sizes of the Cognitive-Functional Composite measures and traditional tests at all follow-up time points
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F IGURE 5 Associations between Cognitive Function Instrument score at 12-month follow-up and annual decline in Cognitive-Functional
Composite, Clinical Dementia Rating Sum of Boxes, Alzheimer’s Disease Assessment Scale–Cognitive subscale, and Alzheimer’s Disease
Cooperation Study–Activity of Daily Living scores. N.B. All x-axis scales represent annual change scores with positive scores reflecting decline
compared to baseline
been statistically derived, and its clinical meaningfulness has not
been demonstrated yet. The same holds true for proposed cognitive
composites,44,45 that have been developed to detect change in preclin-
ical AD. Because those composites do not include a functional com-
ponent, they are probably less useful to track clinical progression in
MCI andmilddementia stages, inwhichevolving functional impairment
plays a key role.26
Comparisons between theCFC subcomponents and traditional cog-
nitive and functional tests revealed that the A-IADL-Q already cap-
tured decline inMCI, whereas the ADCS-ADL did not. This implies that
the A-IADL-Q is more focused on those activities that are prone to
decline in earlier clinical stages.26 Interestingly, comparable sensitiv-
ity to change was observed for the CC and ADAS-Cog. This could be
explained by the fact that those measures partially overlap, and that
changes on the ADAS-Cog score seemed driven by the three memory
subtests that are also included in theCC. This is linewith previous stud-
ies showing that theADAS-Cog subtests that focus on praxis, language,
and confrontation were found to be insensitive to change in MCI and
mild dementia.7 As such, theCCcanbe considered amore concisemea-
sure, as it has a shorter administration time and focuses on the cogni-
tive domains that are vulnerable to early cognitive decline.46
Our finding that the functional component of the CFC detected
clinical progression in individuals with MCI, whereas the cognitive
component did not, may seem counterintuitive as the assumed clinical
trajectory of AD entails that cognitive impairment induces and thereby
precedes functional impairment.47 However, our findings do not
argue against this conceptual understanding of cognitive impairment
preceding functional change, but rather imply that existing paper-and-
pencil cognitive tests may not provide the right tools to capture subtle
cognitive decline. This is in line with previous studies that pointed
toward the limited sensitivity of existing cognitive tests in early clinical
stages of AD.4,48 A functional measure, on the other hand, may be
capable of capturing meaningful decline as reflected by increasing
difficulties in complex activities of daily living.
There are some limitations that should be considered. First, our
results might have been biased by heterogeneity in our sample due
to differences in recruitment strategies employed across the centers.
Themajority of theUMCGcohort included community-based SCD and
MCI participants, who are presumed to be at less risk for developing
dementia compared to those recruited in a memory clinic setting.49
It is therefore likely that those community-based participants showed
less progression in cognition and function over time, as also reflected
by our sensitivity analyses after stratification by study center. As
such, our main analyses on the CFC’s sensitivity to clinical progression
may have been underestimated, especially in the MCI group. The
fact that those community-based individuals did also not decline on
the traditional tests indicates that this limitation was not specific for
the CFC. Second, the sample size of the SCD and DLB groups were
relatively small and thus the power to detect statistical significance
was limited. Hence, no strong interferences can yet be drawn for
the utility of the CFC in these groups. Third, it could be argued that
a follow-up period of 1 year is relatively short to observe evident
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cognitive decline in individuals with MCI or mild AD. However, we
think it is a relevant timeframe as it corresponds to regular follow-up
periods in clinical practice and clinical trial designs, and therefore
it is crucial to know whether the CFC can capture clinical changes
within this timeframe. Finally, it should be noted that the same rater
completed all assessments within one visit andwas therefore not blind
for the cognitive assessments when performing the study partner
interview, and that our CDR-SB assessment was slightly different than
in other studies. However, we do not think that this has affected our
CDR-SB scores, nor our comparisons between the CDR-SB and CFC.
Strengths of this study include our study design that enabled us
to perform an independent validation of the CFC. Furthermore, the
direct comparisons between the CFC and traditional measures is an
important and unique aspect of this study. Additionally, our compar-
ison with an anchor measure of everyday functioning strengthened
the clinical meaningfulness of our findings. This additional investi-
gation has been founded on the concern that statistically significant
effects observed on cognitive tests do not self-evidently demonstrate
clinically meaningful effects.9 It should be acknowledged that our
approach of establishing clinical meaningfulness has limitations, and
that more sophisticated, qualitative methods involving patients and
expert focus groups exist.50 However, we think that the current study
provides a first step to assess the CFC’s clinical meaningfulness.
Finally, sensitivity analyses in the amyloid-positive group enabled us
to explore whether the CFC would be sensitive to AD-specific decline.
However, these findings should be interpreted with caution due to
the relatively small sample size of participants with biomarker data
available, and thus need to be replicated in a larger sample. Altogether,
these aspects will likely enhance future implementation of the CFC in
both AD research and clinical practice.
Future directions include the optimization of the CFC’s sensitivity
to change in MCI, for example by exploring different weights for the
CFC components to create a more sensitive score. Additionally, apply-
ing IRT scoring to the cognitive component might yield more precise
measurement and thereby aid the detection of change over time.51 IRT
has already been applied in the scoring of theA-IADL-Q,which showed
the highest sensitivity to change. Furthermore, IRT would enable us
to use anchor-based bookmarking methods to determine the minimal
important change, which could further establish the clinical meaning-
fulness of the CFC. Additionally, it would be interesting to investigate
the sensitivity of the CFC beyond 1 year of follow-up, with a particular
focus on the SCD and MCI groups. This would allow us to investigate
whether the sensitivity of the CFC could be improved, and whether
the CFC could predict conversion to dementia. To further facilitate the
implementation of the CFC in clinical practice and research, it would
be relevant to develop norms based onCFCperformance in cognitively
normal individuals.
Last, it would be interesting to further investigate the utility of CFC
to measures progression in DLB, given the increasing number of DLB
clinical trials52 and the limited understanding on the clinical course of
DLB so far.53
In conclusion, the current study provides evidence that the CFC
yields an efficient and clinicallymeaningfulmeasure of ADdisease pro-
gression, and therebyhas thepotential to serve as efficacy endpoint for
use inADclinical trials.15,16 Byproviding a concisemeasure of clinically
meaningful cognitive decline, theCFC could contribute to themonitor-
ing of disease progression, which is of relevance for both research and
clinical practice.
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